Besides, studies have also explored an approach to block the MBL pathway by blocking the interaction between MASP‐2 and coronavirus N proteins with anti‐MASP‐2 monoclonal antibodies (nafamostat), which can reduce COVID‐19‐related EC injury and alleviate the risk of inflammation and thrombosis.149. The gene discussed is MASP2; the disease is COVID-19.